3 Next Generation ACOs have left program since January

Three of the 21 participants in CMS's newest accountable care organization (ACO) model have dropped out in the program’s first year, according to data released by the agency.

The first to go was Harrisburg, Pennsylvania-based River Health ACO. After being selected in January, it had said the Next Generation ACO model was “an important step towards advancing models of care that reward value over volume in care delivery.” By February 1, however, the group decided to end its participation, saying “projections do not indicate that the ACO would be able to meet the current target set by CMS,” according to the Central Pennsylvania Business Journal.

WakeMed Key Community Care in Raleigh, North Carolina, and Heritage California ACO in Northridge, Calififornia, were the other two departures. Heritage said in an emailed statement it will “partially participate” in the program this year, with full participation in 2017, though it didn’t explain why it’s scaling back for 2016.

Heritage had previously participated in the Pioneer ACO model from 2012 through 2015. It said it became one of the largest ACOs in the earlier risk-based model, which had seen its fair share of departures, with only nine of the original 32 participants remaining in the program.

CMS is expected to announce the 2017 participants in Next Generation ACO sometime in August. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.